Hemogenyx Pharmaceuticals PLC Macrophage-Directed Therapies Summit Presentation
29 Juli 2024 - 8:00AM
RNS Non-Regulatory
RNS Number : 8674X
Hemogenyx Pharmaceuticals PLC
29 July 2024
29 July 2024
Hemogenyx Pharmaceuticals
plc
("Hemogenyx Pharmaceuticals" or the
"Company")
Presentation at
Macrophage-Directed Therapies Summit
Hemogenyx Pharmaceuticals plc (LSE:
HEMO), the clinical-stage
biopharmaceutical group developing treatments for cancers and viral
diseases, is pleased to announce its participation in the 6th
Macrophage-Directed Therapies Summit ("Summit"), which will be held
on October 1-3, 2024, in Boston, MA. The Company will present its
work on its proprietary Chimeric Bait Receptor ("CBR")
platform.
The Company's CBR platform is an
advanced immunotherapy designed to program or redirect innate
immune cells, such as macrophages, to eliminate specific types of
cancer as well as combat infections from both existing and emerging
viral threats. The Company's presentation at the Summit will focus
on the use of the CBR platform for the treatment of rare
cancers.
Dr. Vladislav Sandler, CEO &
Co-Founder of Hemogenyx Pharmaceuticals, commented: "Our
presentation at the Summit will provide the Company with an
opportunity to further establish its unique position in the
emerging field of myeloid cell therapies. It will also allow us to
exchange ideas with like-minded cell therapy developers, potential
collaborators, and investors."
Enquiries:
Hemogenyx Pharmaceuticals plc
|
https://hemogenyx.com
|
Dr Vladislav Sandler, Chief
Executive Officer & Co-Founder
|
headquarters@hemogenyx.com
|
Peter Redmond, Director
|
peter.redmond@hemogenyx.com
|
|
|
SP
Angel Corporate Finance LLP
|
Tel: +44 (0)20 3470 0470
|
Matthew Johnson, Vadim Alexandre,
Adam Cowl
|
|
|
|
Peterhouse Capital Limited
|
Tel: +44 (0)20 7469 0930
|
Lucy Williams, Duncan Vasey, Charles
Goodfellow
|
|
About Hemogenyx
Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a
publicly traded company (LSE: HEMO) headquartered in London, with
its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and
Immugenyx LLC, located in New York City at its state-of-the-art
research facility.
The Company is a clinical-stage
biopharmaceutical group developing new medicines and treatments for
life-threatening diseases. Hemogenyx Pharmaceuticals is developing
several distinct and complementary product candidates, as well as a
platform technology that it uses as an engine for novel product
development.
This information is provided by Reach, the non-regulatory
press release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NRAEAEXSAAELEFA
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
Von Dez 2023 bis Dez 2024